Beta-Secretase Modulators for Alzheimer's Plaque Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly those targeting beta-secretase mediated disorders, face limitations in effectively reducing beta-amyloid plaque formation and cognitive decline, necessitating the development of new therapeutic agents that can modulate beta-secretase activity.
Innovation Solution
The development of a new class of compounds defined by Formula I, which include stereoisomers, tautomers, and pharmaceutically acceptable salts, capable of modulating beta-secretase activity to reduce the formation of beta-amyloid peptides and subsequent plaque formation in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current beta-secretase treatments are used, then some reduction in beta-amyloid plaque formation may be achieved, but the effectiveness is insufficient to adequately treat Alzheimer's disease and cognitive decline
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of beta-secretase modulators through various substitutions at positions R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20, including different heteroatoms, functional groups, and molecular configurations to optimize enzymatic inhibition effectiveness and plaque reduction capability
Solution Approach 2:
The patent employs composite materials by creating complex molecular structures that combine multiple functional groups and heterocyclic systems within single modulator compounds, enabling simultaneous interaction with multiple targets in the beta-secretase enzyme to enhance both reliability of modulation and productivity of plaque reduction
2Reliability
If new therapeutic agents are developed to modulate beta-secretase activity, then therapeutic effectiveness may be improved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the complex modulator molecule into distinct functional segments or domains, each responsible for specific interactions with the beta-secretase enzyme, allowing systematic optimization of each segment independently while maintaining overall therapeutic effectiveness
Solution Approach 2:
The patent implements universality by designing modular structural elements that can be interchanged or combined in various configurations to create multiple active compounds from a common scaffold, reducing overall complexity while maintaining broad therapeutic effectiveness across different beta-secretase variants
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide a therapeutic approach for treating Alzheimer's disease and other beta-secretase mediated disorders by effectively reducing beta-amyloid plaque formation, potentially slowing cognitive decline and improving treatment outcomes.
Implementation Method 1
Beta secretase (BACE, also commonly referred to as memapsin) is thought to first cleave APP to generate two fragments of the A-beta peptide
Data Source
AI summary
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I) wherein R1, W, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula (I), methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula (I), or compositions including them, to a subject. The invention also comprises further embodiments of Formulas (II) and (III), intermediates and processes useful for the preparation of compounds of the invention.